KFAS
AZN icon

Keating Financial Advisory Services’s AstraZeneca AZN Stock Holding History

Keating Financial Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.9K Buy
368
+333
+951% +$62.6K 0.01% 596
2026
Q1 		$6.9K Sell
35
-269
-88% -$51.9K ﹤0.01% 1273
2025
Q4 		$55.8K Buy
+304
New +$53.3K 0.01% 629

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Keating Financial Advisory Services's AZN Position: Q2 2026 in Review

Keating Financial Advisory Services increased its AstraZeneca (AZN) stake by 951% in Q2 2026, buying an estimated $62.6K and bringing the position to 368 shares worth $69.9K. The position accounts for 0.01% of the portfolio, ranked #596.

Keating Financial Advisory Services first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Keating Financial Advisory Services held 368 shares of AstraZeneca worth $69.9K as of Q2 2026.
  • Keating Financial Advisory Services bought 333 AstraZeneca shares in Q2 2026, an estimated $62.6K.
  • AstraZeneca made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #596 holding.
  • Keating Financial Advisory Services first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.